Bionime Corporation

Taiwan Stock Exchange 4737.TW

Bionime Corporation Operating Cash Flow for the year ending December 31, 2023: USD 6.63 M

Bionime Corporation Operating Cash Flow is USD 6.63 M for the year ending December 31, 2023, a 42.77% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Bionime Corporation Operating Cash Flow for the year ending December 31, 2022 was USD 4.64 M, a -52.29% change year over year.
Bionime Corporation Operating Cash Flow for the year ending December 31, 2021 was USD 9.73 M, a 25.80% change year over year.
Bionime Corporation Operating Cash Flow for the year ending December 31, 2020 was USD 7.73 M, a -42.95% change year over year.
Bionime Corporation Operating Cash Flow for the year ending December 31, 2019 was USD 13.56 M, a 240.13% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Taiwan Stock Exchange: 4737.TW

Bionime Corporation

CEO	Mr. Chun-Mu Huang
IPO Date	Dec. 23, 2010
Location	Taiwan
Headquarters	No. 100, Daqing Street
Employees	1,111
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Drugstores & Retail Pharmacies Hardware & Electronics Musical Instruments Personal Care Pharmaceuticals

Description

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

Key trends

Past 5 years